Advocacy Clinical Trials Pharmaceutical Treatment 
Cannabis Law Report
DECEMBER 3, 2021
–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. RADNOR, Pa.–(BUSINESS
Cannabis Law Report
APRIL 21, 2022
MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
AUGUST 31, 2020
Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi. Program between St.
Cannabis Law Report
SEPTEMBER 21, 2021
He also is a member of the Board of Directors at the Bend Chamber of Commerce and the Chamber’s Advocacy Committee. Do you think there should be a distinction between pharmaceutical cannabis companies vs cannabis grown for adult use retail? . In a perfect world, how would you manage this issue? .
Cannabis Law Report
NOVEMBER 24, 2021
It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). The latter remains a dangerous drug and is considered higher risk for treatment than CBD (TGA 2019 ). Cannabis was more frequently portrayed as a pharmaceutical medicine or drug ( n ?=?11)
The Cannigma
MAY 7, 2021
In Europe, Murphy explains, cannabis products are held to the same standards of accountability and repeatability as other pharmaceuticals. What do those more pharmaceutical standards mean for patients? MSO: Obviously, every country is different but within Europe and certain rainy islands close to it. SM: I think it’s stability.
The Cannigma
DECEMBER 22, 2021
We do participate in clinical trials that are initiated by others, and we will have our own clinical trial using terpene formulations in oil. We have, I think, eight PhDs. We have an excellent set of in-house laboratories. We do most of our research initially ourselves.
Expert insights. Personalized for you.
52 
Let's personalize your content